The FDA clarified Thursday that it won't take action against GLP-1 compounders for certain violations while it reevaluates Eli Lilly's weight loss and diabetes drug ...
'FDA Won't Take Action Against GLP-1 Compounders As It Rethinks Tirzepatide Shortage' - Endpoints News
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated